Protocol Ledger

NCT04563026 · Phase II · COMPLETED

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

Interventional Phase II clinical trial protocol NCT04563026 sponsored by Durect in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-22 Enrollment: 307 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04563026
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)307 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04563026
Protocol FieldVerified Registry Value
NCT IdentifierNCT04563026
Consolidated Lead SponsorDurect
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment307 participants (ACTUAL)
Registered Start Date2021-01-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI